Next-Generation Profile Successor compound to semaglutide and tirzepatide in mechanism breadth - currently in Phase III trials globally as of 2024
This renewed focus on non-COVID indications earlier in development may lead to more self-injection options, such as OTS autoinjectors. Over the past year, devices assembled at Catalent for customers have included anti-needlestick devices and autoinjectors for biologics used to treat autoimmune disorders
This dual mechanismsurgical restriction plus hormonal appetite suppressionaddresses weight loss from two independent angles, potentially achieving outcomes that surgery alone cannot reach
They prevent strokes, heart attacks, chronic kidney disease, sleep apnea, and Parkinson's disease
Vicky Chuong, Mehdi Farokhnia, Sophia Khom, Claire L
Switching Injection Sites to Reduce GLP-1 Nausea Though there is no scientific evidence supporting the idea that changing the injection site reduces nausea, some patients have reported a possible reduction in nausea by rotating their injection sites